Peptide pioneers forge new collaboration

8 February 2016

Japanese drug firms PeptiDream (TYO: 4587) and Shionogi (TYO: 4507) have teamed up to develop new peptide-based treatments.

Tokyo based PeptiDream will use its Peptide Discovery Platform System (PDPS) to identify macrocyclic/constrained peptides against multiple targets selected by Shionogi. It will then optimize hit peptides into therapeutic peptides or small molecule products which Shionogi will have the right to develop and commercialize.

PeptiDream will receive an undisclosed upfront payment and research funding as part of the deal and will also be in line for payments linked to achievement of certain preclinical and clinical development milestones. The company will also receive royalties on sales of any products that arise from the collaboration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK